Bone Matrix Proteoglycans in Skeletal Function - Osteogenesis Imperfecta - page 85

[18] Park PW, Reizes O, Bernield M. Cell surface heparan sulfate
proteoglycans: selective regulators of ligand-receptor encoun-
ters. J Biol Chem 2000;275(39):29923-26.
[19] Grzesik WJ, Frazier CR, Shapiro JR, Sponseller PD, Robey PG,
Fedarko NS. Age-related changes in human bone proteogly-
can structure. Impact of osteogenesis imperfecta. J Biol Chem
2002;277(46):43638-47.
[20] Schonherr E, Sunderkotter C, Iozzo RV, Schaefer L. Decorin,
a novel player in the insulin-like growth factor system. J Biol
Chem 2005;280(16):15767-72.
[21] Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J,
Sorokin L, et al. Decorin-mediated regulation of ibrillin-1 in the
kidney involves the insulin-like growth factor-I receptor and
mammalian target of rapamycin. Am J Pathol 2007;170(1):301-15.
[22] Schonherr E, Levkau B, Schaefer L, Kresse H, Walsh K. Decorin-
mediated signal transduction in endothelial cells. Involvement
of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1)
but not p27(KIP1). J Biol Chem 2001;276(44):40687-92.
[23] Schaefer L, Iozzo RV. Biological functions of the small leucine-
rich proteoglycans: from genetics to signal transduction. J Biol
Chem 2008;283(31):21305-09.
[24] McEwan PA, Scott PG, Bishop PN, Bella J. Structural correla-
tions in the family of small leucine-rich repeat proteins and
proteoglycans. J Struct Biol 2006;155(2):294-305.
[25] Shimizu-Hirota R, Sasamura H, Kuroda M, Kobayashi E,
Saruta T. Functional characterization of podocan, a member
of a new class in the small leucine-rich repeat protein family.
FEBS Lett 2004;563(1-3):69-74.
[26] Vogel KG, Paulsson M, Heinegard D. Speciic inhibition of
type I and type II collagen ibrillogenesis by the small proteo-
glycan of tendon. Biochem J 1984;223(3):587-97.
[27] Rada JA, Cornuet PK, Hassell JR. Regulation of corneal colla-
gen ibrillogenesis in vitro by corneal proteoglycan (lumican
and decorin) core proteins. Exp Eye Res 1993;56(6):635-48.
[28] Kalamajski S, Oldberg A. Homologous sequence in lumican
and ibromodulin leucine-rich repeat 5-7 competes for collagen
binding. J Biol Chem 2009;284(1):534-9.
[29] Kalamajski S, Oldberg A. Fibromodulin binds collagen type I
via Glu-353 and Lys-355 in leucine-rich repeat 11. J Biol Chem
2007;282(37):26740-45.
[30] Svensson L, Heinegard D, Oldberg A. Decorin-binding sites for
collagen type I are mainly located in leucine-rich repeats 4-5.
J Biol Chem 1995;270(35):20712-16.
[31] Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M,
Krzyzankova M, et al. The matrix component biglycan is pro-
inlammatory and signals through Toll-like receptors 4 and 2 in
macrophages. J Clin Invest 2005;115(8):2223-33.
[32] Tillgren V, Onnerfjord P, Haglund L, Heinegard D. The tyrosine
sulfate-rich domains of the LRR proteins ibromodulin and
osteoadherin bind motifs of basic clusters in a variety of hep-
arin-binding proteins, including bioactive factors. J Biol Chem
2009;284(42):28543-53.
[33] Henry SP, Takanosu M, Boyd TC, Mayne PM, Eberspaecher H,
Zhou W, et al. Expression pattern and gene characterization of
asporin. A newly discovered member of the leucine-rich repeat
protein family. J Biol Chem 2001;276(15):12212-21.
[34] Kalamajski S, Oldberg A. The role of small leucine-rich pro-
teoglycans in collagen ibrillogenesis. Matrix Biol 2010;
29(4):248-53.
[35] Schonherr E, Witsch-Prehm P, Harrach B, Robenek H,
Rauterberg J, Kresse H. Interaction of biglycan with type I col-
lagen. J Biol Chem 1995;270(6):2776-83.
[36] Douglas T, Heinemann S, Bierbaum S, Scharnweber D, Worch H.
Fibrillogenesis of collagen types I, II, and III with small leucine-
rich proteoglycans decorin and biglycan. Biomacromolecules
2006;7(8):2388-93.

[37] Svensson L, Aszodi A, Reinholt FP, Fassler R, Heinegard D,
Oldberg A. Fibromodulin-null mice have abnormal collagen
ibrils, tissue organization, and altered lumican deposition in
tendon. J Biol Chem 1999;274(14):9636-47.
[38] Wiberg C, Heinegard D, Wenglen C, Timpl R, Morgelin M.
Biglycan organizes collagen VI into hexagonal-like networks
resembling tissue structures. J Biol Chem 2002;277(51):49120-26.
[39] Geng Y, McQuillan D, Roughley PJ. SLRP interaction can pro-
tect collagen ibrils from cleavage by collagenases. Matrix Biol
2006;25(8):484-91.
[40] Ruoslahti E. Structure and biology of proteoglycans. Annu Rev
Cell Biol 1988;4:229-55.
[41] Danielson KG, Baribault H, Holmes DF, Graham H,
Kadler KE, Iozzo RV. Targeted disruption of decorin leads to
abnormal collagen ibril morphology and skin fragility. J Cell Biol
1997;136(3):729-43.
[42] Corsi A, Xu T, Chen XD, Boyde A, Liang J, Mankani M, et al.
Phenotypic effects of biglycan deiciency are linked to collagen
ibril abnormalities, are synergized by decorin deiciency, and
mimic Ehlers-Danlos-like changes in bone and other connec-
tive tissues. J Bone Miner Res 2002;17(7):1180-9.
[43] Ezura Y, Chakravarti S, Oldberg A, Chervoneva I, Birk DE.
Differential expression of lumican and ibromodulin regulate
collagen ibrillogenesis in developing mouse tendons. J Cell
Biol 2000;151(4):779-88.
[44] Robbins JR, Vogel KG. Regional expression of mRNA
for proteoglycans and collagen in tendon. Eur J Cell Biol
1994;64(2):264-70.
[45] Ameye L, Aria D, Jepsen K, Oldberg A, Xu T, Young MF.
Abnormal collagen ibrils in tendons of biglycan/ibromodu-
lin-deicient mice lead to gait impairment, ectopic ossiication,
and osteoarthritis. FASEB J 2002;16(7):673-80.
[46] Zhang G, Chen S, Goldoni S, Calder BW, Simpson HC, Owens
RT, et al. Genetic evidence for the coordinated regulation of
collagen ibrillogenesis in the cornea by decorin and biglycan.
J Biol Chem 2009;284(13):8888-97.
[47] Takeuchi Y, Kodama Y, Matsumoto T. Bone matrix decorin
binds transforming growth factor-beta and enhances its bioac-
tivity. J Biol Chem 1994;269(51):32634-38.
[48] Bianco P, Fisher LW, Young MF, Termine JD, Robey PG.
Expression and localization of the two small proteoglycans
biglycan and decorin in developing human skeletal and non-
skeletal tissues. J Histochem Cytochem 1990;38(11):1549-63.
[49] Ingram RT, Clarke BL, Fisher LW, Fitzpatrick LA. Distribution
of noncollagenous proteins in the matrix of adult human bone:
evidence of anatomic and functional heterogeneity. J Bone
Miner Res 1993;8(9):1019-29.
[50] Xu T, Bianco P, Fisher LW, Longenecker G, Smith E,
Goldstein S, et al. Targeted disruption of the biglycan gene
leads to an osteoporosis-like phenotype in mice. Nat Genet
1998;20(1):78-82.
[51] Heegaard AM, Corsi A, Danielsen CC, Nielsen KL,
Jorgensen HL, Riminucci M, et al. Biglycan deiciency causes
spontaneous aortic dissection and rupture in mice. Circulation
2007;115(21):2731-8.
[52] Ameye L, Young MF. Mice deicient in small leucine-rich pro-
teoglycans: novel in vivo models for osteoporosis, osteoarthri-
tis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal
diseases. Glycobiology 2002;12(9):107R-116RR.
[53] Bi Y, Nielsen KL, Kilts TM, Yoon A, Karsdal MA,
Wimer HF, et al. Biglycan deiciency increases osteoclast differ-
entiation and activity due to defective osteoblasts. Bone 2006;
38(6):778-86.
[54] Kou I, Nakajima M, Ikegawa S. Expression and regulation
of the osteoarthritis-associated protein asporin. J Biol Chem
2007;282(44):32193-99.